Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: Remdesivir IV 200 mg once then 100 mg once daily for 9 days

Generated Narrative: Group 179783

version: 3; Last updated: 2023-12-04 20:29:22+0000

Profile: ExposureDefinition

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: Remdesivir IV 200 mg once then 100 mg once daily for 9 days [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179783. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179783. Computable resource at: https://fevir.net/resources/Group/179783.)

Artifact Author: Brian S. Alper:

url: https://fevir.net/resources/Group/179783

identifier: FEvIR Object Identifier/179783

name: Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days

title: Remdesivir IV 200 mg once then 100 mg once daily for 9 days

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Remdesivir IV 200 mg once then 100 mg once daily for 9 days

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

membership: Conceptual

Characteristics

-CodeValue[x]ExcludeDescription
*Defined by ReferenceIV remdesivir 200 mg then 100 mg/day for 9 daysfalse

Remdesivir IV 200 mg once then 100 mg once daily for 9 days